Drug Profile
PF 0713
Alternative Names: PF0713Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator PharmacoFore
- Developer Ensysce Biosciences
- Class Anaesthetics
- Mechanism of Action GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Anaesthesia; Chemotherapy-induced nausea and vomiting; Postoperative nausea and vomiting; Radiotherapy-induced nausea and vomiting; Sedation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Anaesthesia in USA (IV, Infusion)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Sedation in USA (IV, Infusion)
- 16 Jul 2016 No recent reports of development identified for research development in Chemotherapy-induced-nausea-and-vomiting in USA (IV, Infusion)